OncoSec Medical (NASDAQ:ONCS) was downgraded by equities researchers at HC Wainwright from a “buy” rating to a “neutral” rating in a research report issued on Wednesday, Marketbeat.com reports.
A number of other research firms also recently weighed in on ONCS. Dawson James reissued a “buy” rating on shares of OncoSec Medical in a report on Monday, July 16th. Piper Jaffray Companies increased their target price on OncoSec Medical to $5.00 and gave the company an “overweight” rating in a report on Tuesday, August 14th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $4.00.
ONCS stock opened at $0.84 on Wednesday. OncoSec Medical has a fifty-two week low of $0.68 and a fifty-two week high of $2.95. The stock has a market capitalization of $51.72 million, a price-to-earnings ratio of -0.79 and a beta of 2.28.
About OncoSec Medical
OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer.
See Also: What are the Benefits of Index Funds?
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.